Targeting JAK2 in Myeloproliferative Neoplasms

Experts discuss the differences between essential thrombocythemia [ET], polycythemia vera [PV], and myelofibrosis [MF] and refinement of diagnosis.

Dr Verstovsek and Dr Kuykendall discuss the limitations of past treatments for MPNs.

A discussion of the role of the JAK2 mutation and other factors in the development of MPNs.

The progression of disease in MPNs and how genetic testing may inform therapy.

Response criteria, quality of life issues, and therapeutic options including ruxolitinib, hydroxyurea, and interferon are discussed in the context of ET.

Additional treatment options for low- and high-risk patients with MPNs are discussed.

Efficacy and safety profiles of therapies for PV are discussed, along with results of the RESPONSE and RESPONSE-2 studies.

A discussion of JAK inhibitors, risk models, quality of life, splenomegaly, and other issues in treating patients with MF.

Alternative dosing schedules and the use of JAK inhibitors for patients with MPNs in the second-line setting are explored.

Combination trials and new agents for MPNs, such as parsaclisib and momelotinib, are discussed in the context of recent ASCO presentations.

The doctors discuss withdrawing patients with MPNs from a JAK inhibitor, titration, and rechallenging.

The experts describe a new drug under review by the FDA that offers an option for patients with MPNs and low platelets and discuss what they are looking forward to in the next 3-5 years.

The doctors discuss new discoveries that may lead to a cure for MPNs.